Vaxcyte Inc. reported Phase I/II clinical trial results in adults on 3 September for VAX-31, its pneumococcal conjugate vaccine (PCV) against 31 serotypes of Streptococcus pneumoniae, meeting immunogenicity requirements needed for approval across all serotypes and achieving non-inferiority or superiority compared to Pfizer Inc.’s market-leading product Prevar 20 across all of the vaccines’ shared serotypes. If eventually approved, Vaxcyte’s VAX-31 would offer the broadest protection against pneumococcal disease.
Vaxcyte Confident Of Pneumococcal Vaccine Dominance After Phase I/II Results
Phase III Adult Trials To Begin In 2025
Listen to this article
The company’s VAX-31 against 31 pneumococcal serotypes outperformed Pfizer’s market-leading Prevnar 20 and could provide the broadest coverage of any vaccine in its class.
Keep up with the top pharma business news of the week. On the go.
More from Clinical Trials
• By
Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.
• By
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Sponsored By:
The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains